Ivim Health Welcomes FDA’s Long-Overdue Step Toward Regulated Peptide Access
Anthony Kantor, Dr. Taylor Kantor, and Dr. Jessica Duncan —
We applaud today’s announcement from Secretary Kennedy on peptide reclassification. This is meaningful news for the patients we serve every day. For too long, Americans interested in peptide therapy have had limited options for accessing these treatments through legitimate, clinically supervised channels. Moving these substances toward a proper regulatory review process is a step toward changing that — and we’re excited to soon be able to offer peptide access to our patients through a trusted, physician-led model.
At Ivim Health, our physician-led model has always been built around one principle: that access to emerging treatments should never come at the expense of safety or clinical oversight. We believe peptide therapies hold real promise for metabolic health and longevity, and we’ve been committed to advancing that work responsibly, with board-certified physicians guiding every patient’s care.
This is also personal for us. Peptide therapy is one of the main reasons Ivim exists. From our earliest days, it was central to the care we offered patients — long before it became a mainstream conversation. Anthony and Taylor’s own mother has been able to manage her Crohn’s disease in ways she couldn’t before peptide therapy. That experience shaped everything about how we think about this space — not as a wellness trend, but as a category of treatment that deserves the same rigor and respect as any other medicine. Patients like Lori deserve a legitimate pathway. Today’s announcement moves us closer to that.
The opportunity in front of us isn’t just regulatory clarity — it’s the chance to show patients what thoughtful, evidence-based access to these treatments actually looks like. As the FDA’s expert panels evaluate each substance on the science, we’ll be watching closely and preparing to expand our offerings in ways that reflect the clinical rigor our patients expect and deserve.
